ProQR Therapeutics NV

NASDAQ:PRQRUnited States

Ratings actions from Benzinga: https://www.benzinga.com/quote/PRQR/analyst-ratings

(END) Dow Jones Newswires

November 08, 2024 07:44 ET (12:44 GMT)

-- Results related to financial liabilities measured at fair value through profit or loss (139) (117) (266) (1,008) ---------- --------- ---------- --------- -- Income tax expenses -- (83) (197) (83) ---------- --------- ---------- --------- Changes in working capital 1,117 (2,008) (12,721) 46,660 ---------- --------- ---------- --------- Cash (used in) / generated by operations (6,299) (8,393) (29,046) 25,120 ---------- --------- ---------- --------- Corporate income tax received 1 83 197 83 ---------- --------- ---------- --------- Interest received 860 802 2,402 1,667 ---------- --------- ---------- --------- Interest paid (219) -- (598) -- ---------- --------- ---------- --------- Net cash (used in) / generated by operating activities (5,657) (7,508) (27,045) 26,870 ---------- --------- ---------- --------- Cash flow from investing activities Increase in financial asset - current -- -- (17,000) -- ---------- --------- ---------- --------- Decrease in financial asset - current 17,000 -- 17,000 -- ---------- --------- ---------- --------- Purchases of property, plant and equipment (286) (339) (1,285) (769) ---------- --------- ---------- --------- Proceeds from sale of property, plant and equipment -- -- -- 47 ---------- --------- ---------- --------- Net cash generated by / (used in) investing activities 16,714 (339) (1,285) (722) ---------- --------- ---------- --------- Cash flow from financing activities ---------- --------- ---------- --------- Proceeds from exercise of share options 1 151 175 155 ---------- --------- ---------- --------- Repayment of lease liability (454) (432) (1,329) (1,338) ---------- --------- ---------- --------- Net cash used in financing activities (453) (281) (1,154) (1,183) ---------- --------- ---------- --------- Net increase / (decrease) in cash and cash equivalents 10,604 (8,128) (29,484) 24,965 ---------- --------- ---------- --------- Currency effect cash and cash equivalents (173) 118 (40) 812 ---------- --------- ---------- --------- Cash and cash equivalents, at beginning of the period 78,970 128,562 118,925 94,775 ---------- --------- ---------- --------- Cash and cash equivalents at the end of the period 89,401 120,552 89,401 120,552 ---------- --------- ----------